This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Lerociclib
- DrugBank Accession Number
- DB16218
- Background
Lerociclib is under investigation in clinical trial NCT02983071 (G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast Cancer).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Lerociclib (DB16218)
- Weight
- Average: 474.613
Monoisotopic: 474.285557747 - Chemical Formula
- C26H34N8O
- Synonyms
- G1t38 free base
- Lerociclib
- External IDs
- G1T38
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- WBH8AY6ENB
- CAS number
- 1628256-23-4
- InChI Key
- YPJRHEKCFKOVRT-UHFFFAOYSA-N
- InChI
- InChI=1S/C26H34N8O/c1-18(2)32-10-12-33(13-11-32)20-6-7-22(27-16-20)30-25-28-15-19-14-21-24(35)29-17-26(8-4-3-5-9-26)34(21)23(19)31-25/h6-7,14-16,18H,3-5,8-13,17H2,1-2H3,(H,29,35)(H,27,28,30,31)
- IUPAC Name
- 12'-({5-[4-(propan-2-yl)piperazin-1-yl]pyridin-2-yl}amino)-2',5',11',13'-tetraazaspiro[cyclohexane-1,3'-tricyclo[7.4.0.0^{2,7}]tridecane]-1'(13'),7',9',11'-tetraen-6'-one
- SMILES
- CC(C)N1CCN(CC1)C1=CC=C(NC2=NC=C3C=C4N(C3=N2)C2(CCCCC2)CNC4=O)N=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 68007293
- BindingDB
- 253941
- ChEMBL
- CHEMBL3904602
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Withdrawn Treatment Endometrial Carcinoma 1 2 Active Not Recruiting Treatment Advanced Breast Cancer 1 1 Completed Other Healthy Subjects (HS) 1 1, 2 Active Not Recruiting Treatment Breast Cancer / Breast Neoplasms / Ductal Breast Carcinoma 1 1, 2 Completed Treatment Lung Cancer / Non-Small Cell Lung Cancer (NSCLC) / Non-Small Cell Lung Carcinoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.134 mg/mL ALOGPS logP 3.49 ALOGPS logP 3.51 Chemaxon logS -3.6 ALOGPS pKa (Strongest Acidic) 11.59 Chemaxon pKa (Strongest Basic) 8.19 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 91.21 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 137.68 m3·mol-1 Chemaxon Polarizability 54.61 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at December 15, 2020 18:15 / Updated at February 21, 2021 18:55